Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, ABI Shareholders Approve Merger

NEW YORK (GenomeWeb News) – Invitrogen and Applied Biosystems announced separately today that their respective shareholders have voted in favor of the firms’ $6.7 billion merger.
 
Both firms said that around 98 percent of their respective shares were cast in favor of the deal, which is expected to close next month. The transaction already has cleared US antitrust hurdles but still requires clearance from European Union regulators.
 
As reported by GenomeWeb Daily News on Oct. 9, Invitrogen increased its expectations for first-year post-merger cost synergies to $80 million from $60 million. It said today that it remains committed to achieving that goal.
 
Invitrogen also said that the current issues affecting capital markets are not anticipated to have an impact on financing for the deal.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.